Form 4: Denali Therapeutics Executive Alexander Schuth Reports Stock and Option Transactions

Alexander Schuth, COFO and Secretary of Denali Therapeutics, reported the acquisition of restricted stock units and stock options, as well as adjustments to his holdings.

Summary

• Alexander Schuth, the COFO and Secretary of Denali Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On January 3, 2025, Schuth acquired 54,180 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock.
• These RSUs vest over four years, with 25% vesting on January 3, 2026, and the remaining 75% vesting annually thereafter, contingent on continued service.
• Schuth also acquired 162,540 stock options with an exercise price of $21.26, vesting over four years with 25% vesting on January 3, 2026, and the remainder vesting monthly.
• The report also indicates that Schuth indirectly owns 523,749 shares of common stock through The Schuth Family Trust.
• The transactions were made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider transactions, which are generally viewed neutrally to slightly positive as they align executive interests with company performance.

Positives

• The acquisition of RSUs and stock options suggests continued alignment of executive interests with the company's long-term performance.
• The vesting schedules for both RSUs and options encourage long-term commitment from the executive.

Risks

• The vesting of RSUs and options is contingent on Schuth's continued service with the company, creating a potential risk if he were to leave before full vesting.

Industry Context

Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders. This filing is typical for executives receiving equity-based compensation.

Comparison to Industry Standards

• The vesting schedules for the RSUs and stock options are fairly standard for executive compensation packages in the biotechnology industry.
• Many companies use a four-year vesting schedule with a one-year cliff, similar to the structure reported here.

Stakeholder Impact

• The transactions do not have a direct impact on stakeholders, but the vesting schedules encourage long-term value creation, which is beneficial for shareholders.

Key Dates

Keywords

Form 4, Denali Therapeutics, Alexander Schuth, Restricted Stock Units, Stock Options, Beneficial Ownership, Executive Compensation, Vesting